Please use this identifier to cite or link to this item: http://e.ieu.edu.ua/handle/123456789/593
Full metadata record
DC FieldValueLanguage
dc.contributor.authorOlczak-Pruc, Monika.;-
dc.contributor.authorSzarpak, Lukasz.;-
dc.contributor.authorNavolokina, Alla.;-
dc.contributor.authorChmielewski, Jaroslaw.;-
dc.contributor.authorPanasiuk, Lech.;-
dc.contributor.authorJuárez-Vela, Raúl.;-
dc.contributor.authorPruc, Michal.;-
dc.contributor.authorSwieczkowski, Damian.;-
dc.contributor.authorMajer, Ryszard.;-
dc.contributor.authorRafique, Zubaid.;-
dc.contributor.authorPeacock, Frank William.;-
dc.date.accessioned2023-05-31T08:37:20Z-
dc.date.available2023-05-31T08:37:20Z-
dc.date.issued2022-
dc.identifier.citationAnnals of Agricultural and Environmental Medicine-2022.uk
dc.identifier.urihttp://e.ieu.edu.ua/handle/123456789/593-
dc.description.abstractIntroduction and Objective. Zinc is a trace element that plays a role in stimulating innate and acquired immunity. The aim of the study was to determine the antiviral effect of the administration of zinc in COVID-19 patients. Materials and Method. A literature search was performed in P Web of Science, PubMed, Scopus and Cochrane databases from 1 January 2020 – 22 August 2022. In addition, reference lists of the included articles and their related citations in PubMed were also reviewed for additional pertinent studies. Results. A total of 9 eligible studies were identified. In-hospital mortality in zinc supplementation patients, and patients treated without zinc, varied and amounted to 21.6% vs. 23.04% difference (OR=0.71; 95%CI: 0.62–0.81; p<0.001). 28-day to 30-day mortality in patients treated with zinc was 7.7%, compared to 11.9% for patients treated without zinc (OR=0.61; 95%CI: 0.35–1.06; p=0.08). In-hospital adverse events among patients treated with and without COVID-19 did not show any statistically significant differences in relation to acute kidney injury occurrence (12.8% vs. 12.4%, respectively; OR=0.63; 95%CI: 0.19–2.12; p=0.45, as well as need for mechanical ventilation (13.2% vs. 14.1%; OR=0.83; 95%CI: 0.52–1.32; p=0.43). Conclusions. Zinc supplementation is associated with lower COVID-19 in-hospital mortality. Additionally, it is risk-free in COVID-19 patients since there have been no negative side effects, such as acute renal damage or the requirement for mechanical ventilation compared to patients without COVID-19. Due to scientific evidence and the role it represents in the human body, zinc supplementation should be taken into consideration for COVID-19 patients as an adjunct therapyuk
dc.language.isoenuk
dc.publisherAnnals of Agricultural and Environmental Medicineuk
dc.subjectmeta-analysis,uk
dc.subjectzinc,uk
dc.subjectsupplementation,uk
dc.subjectCOVID-19,uk
dc.subjectSARS-CoV-2;uk
dc.titleThe effect of zinc supplementation on the course of COVID-19 – A systematic review and meta-analysis.uk
dc.typeArticleuk
Appears in Collections:Європейська медична школа

Files in This Item:
File Description SizeFormat 
AAEM-01136-2022-02-proof-4-E.pdf1.47 MBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Admin Tools